Ownership Capital B.V. Lowers Stock Position in Insulet Co. (NASDAQ:PODD)

Ownership Capital B.V. lessened its position in shares of Insulet Co. (NASDAQ:PODD) by 17.6% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 193,894 shares of the medical instruments supplier’s stock after selling 41,474 shares during the period. Insulet makes up approximately 1.4% of Ownership Capital B.V.’s portfolio, making the stock its 23rd largest position. Ownership Capital B.V.’s holdings in Insulet were worth $45,129,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Insulet in the 2nd quarter valued at $32,000. UMB Bank n.a. boosted its stake in Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the last quarter. CVA Family Office LLC grew its holdings in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its position in shares of Insulet by 159.2% in the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 156 shares during the last quarter.

Insulet Stock Performance

NASDAQ PODD opened at $268.00 on Friday. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet Co. has a fifty-two week low of $151.56 and a fifty-two week high of $275.52. The business has a fifty day moving average of $232.01 and a 200-day moving average of $204.22. The stock has a market cap of $18.79 billion, a price-to-earnings ratio of 48.73, a price-to-earnings-growth ratio of 4.47 and a beta of 1.22.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. During the same period in the previous year, the company posted $0.38 EPS. The business’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, analysts predict that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PODD shares. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday. They set an “outperform” rating and a $300.00 price objective for the company. Raymond James upped their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Barclays lifted their price objective on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Citigroup upped their target price on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Finally, Canaccord Genuity Group raised their target price on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $246.80.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.